Armodafinil

證據等級: L5

預測適應症: 1 個

Armodafinil: From Excessive Sleepiness to Insomnia

One-Sentence Summary

Armodafinil (Nuvigil) is the R-enantiomer of modafinil, a wakefulness-promoting agent approved in the US for excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work sleep disorder. The TxGNN model predicts it may be effective for Insomnia, with 12 clinical trials and 19 publications currently supporting this direction. While seemingly counterintuitive, emerging evidence suggests armodafinil may benefit insomnia in specific populations — particularly cancer survivors and patients with comorbid sleep-disordered breathing — by normalizing the disrupted sleep-wake cycle.

Quick Overview

Item	Content
Original Indication	Excessive sleepiness (narcolepsy, obstructive sleep apnea, shift work sleep disorder)
Predicted New Indication	Insomnia
TxGNN Prediction Score	99.89%
Evidence Level	L2
India Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. Based on known published information, Armodafinil is the longer-lasting R-enantiomer of modafinil — a wakefulness-promoting agent believed to act primarily through inhibition of the dopamine transporter (DAT), with secondary activity on norepinephrine, serotonin, and orexin/hypocretin systems. This makes it pharmacologically distinct from classic amphetamine-type stimulants. Its three FDA-approved indications all involve a core deficit of excessive daytime sleepiness, and its use for insomnia in this context may appear paradoxical at first glance.

However, insomnia and excessive sleepiness frequently co-exist in the same patient — especially in oncology populations after chemotherapy, where disrupted circadian rhythms cause simultaneous daytime fatigue and nighttime wakefulness. By consolidating wakefulness during the day, armodafinil may restore sleep pressure and improve nighttime sleep architecture, producing a beneficial secondary effect on insomnia. This “bi-directional” sleep-wake normalization hypothesis is directly tested in at least three Phase 2 randomised trials involving breast cancer survivors.

Furthermore, shift work sleep disorder — one of armodafinil’s approved indications — inherently encompasses an insomnia component (inability to sleep at non-traditional hours). The TxGNN model’s high-confidence prediction is therefore mechanistically plausible within the broader sleep medicine framework, and the clinical evidence base, while targeted at specific populations, provides meaningful support for exploratory investigation into general insomnia.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02552303	N/A	Completed	39	Direct insomnia study: Armodafinil vs CBT-I vs combination for insomnia comorbid with obstructive sleep apnea; assessed sleep continuity and CPAP adherence
NCT01019187	Phase 2	Completed	226	Randomised Phase 2: CBT-I ± armodafinil for insomnia and fatigue in breast cancer survivors post-chemotherapy
NCT01091974	Phase 2	Completed	138	Four-arm RCT of CBT-I and armodafinil in breast cancer patients with post-chemotherapy sleep disturbances
NCT01011218	Phase 2	Completed	70	Pilot study of BBT-I ± armodafinil 150 mg/day for insomnia in breast cancer patients during active cancer treatment
NCT01080807	Phase 4	Completed	385	Armodafinil 150 mg for shift work disorder: improved clinical condition late in shift including the commute home; functional and patient-reported outcomes
NCT01305408	Phase 3	Completed	399	Armodafinil 150 mg/day adjunctive to mood stabilisers for major depression in Bipolar I Disorder
NCT01072929	Phase 3	Completed	433	Armodafinil 150/200 mg/day adjunctive therapy for major depression associated with Bipolar I Disorder
NCT01072630	Phase 3	Completed	492	Armodafinil 150/200 mg/day vs placebo for Bipolar I major depression; additional data on sleep-related outcomes
NCT00678691	Phase 4	Completed	55	Armodafinil augmentation for fibromyalgia-related fatigue; builds on off-label evidence for fatigue/sleep disruption management
NCT00481195	Phase 2	Completed	257	Armodafinil 150 mg/day adjunctive therapy for inadequately responsive Bipolar I major depression

Literature Evidence

PMID	Year	Type	Journal	Key Findings
39535843	2024	Review	Expert Opinion on Pharmacotherapy	Comprehensive review of pharmacological and non-pharmacological management of sleep disturbances; discusses wakefulness-promoting agents including armodafinil class
24312590	2013	Meta-analysis	PLoS ONE	Systematic review and meta-analysis confirming modafinil (parent compound) efficacy for fatigue and excessive daytime sleepiness in neurological disorders
27010071	2016	Systematic Review	Parkinsonism & Related Disorders	Systematic review of pharmacological interventions for daytime sleepiness and sleep disorders; highlights evidence gaps for insomnia treatment
18729534	2008	Review	Drugs	Evidence-based review of approved and investigational uses of modafinil covering narcolepsy, shift work disorder, fatigue, and off-label applications
24272458	2014	Review	Neurotherapeutics	Review of treatment options for sleep disorders in comorbid populations; CBT and pharmacotherapy for insomnia discussed alongside wakefulness-promoting agents
22021174	2011	Systematic Review	Movement Disorders	MDS Evidence-Based Medicine review covering non-motor symptoms treatment; evaluates evidence for sleep dysfunction including insomnia and hypersomnia
17181377	2006	Review	Drugs	Shift work sleep disorder: burden of illness and management including modafinil-class agents for both the sleepiness and insomnia components
21904092	2011	Review	Postgraduate Medicine	Emerging therapies for shift work disorder, specifically noting armodafinil for the dual presentation of excessive sleepiness and insomnia
24138359	2013	Review	Medical Journal of Australia	Sleep loss and circadian disruption in shift work; highlights insomnia as a core co-morbidity alongside SWD and discusses management principles
20166851	2010	Review	Expert Opinion on Emerging Drugs	Emerging treatments for narcolepsy and related disorders; describes pharmacological profile of modafinil/armodafinil relevant to sleep-wake regulation

India Market Information

Armodafinil is currently not marketed in India. No product registrations were identified in the CDSCO database (total licences: 0). Any clinical development or use pathway would require a new regulatory submission to CDSCO for import or manufacture approval.

Safety Considerations

Drug Interactions: Armodafinil has 170 known drug interactions on record. The most clinically significant are summarised below:

Severity	Interacting Drugs
Moderate	Rabeprazole, Esomeprazole, Dexamethasone, Cisapride, Eliglustat, Linagliptin
Minor	Hydrocortisone, Pioglitazone, Aprepitant, Triamcinolone, Betamethasone, Cimetidine, Clarithromycin, Clotrimazole, Dronabinol, Miconazole, Naldemedine, Naloxegol, Nitisinone, Granisetron

Key interaction mechanisms to note:

CYP2C19 inhibition: Armodafinil inhibits CYP2C19, increasing plasma levels of proton pump inhibitors (Rabeprazole, Esomeprazole) — relevant in oncology populations often on GI prophylaxis
CYP3A4 induction: Armodafinil induces CYP3A4, potentially reducing efficacy of co-administered drugs metabolised by this pathway (Cisapride, Eliglustat)
Corticosteroid interactions: Multiple corticosteroids show Minor interactions; monitoring is advised in cancer patients on steroid regimens

Please refer to the full package insert for complete warnings and contraindications, as this data was not available in the current evidence pack.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The TxGNN prediction score of 99.89% is strongly supportive, and the evidence base includes multiple completed Phase 2 RCTs directly targeting insomnia (particularly in cancer populations), as well as one dedicated study for insomnia comorbid with sleep-disordered breathing. Armodafinil’s established safety and tolerability profile from approved sleep disorder indications provides a meaningful foundation. However, armodafinil is not currently marketed in India, detailed MOA data is absent, and Phase 3 evidence specific to insomnia (as opposed to bipolar depression or SWD) has not yet been generated.

To proceed, the following is needed:

Retrieve complete MOA data from DrugBank to formally substantiate the biological link between wakefulness promotion and insomnia improvement
Obtain and review the full package insert for key warnings and contraindications (blocking data gap)
Define the target insomnia subpopulation: cancer survivors, shift workers, or sleep-disordered breathing patients have the strongest existing evidence; broad general insomnia requires a dedicated trial
Design a Phase 3 RCT in the identified population to elevate evidence from L2 to L1
Assess CDSCO regulatory pathway for new drug registration or import licence in India
Conduct comprehensive DDI screening for the 170 known interactions in the context of typical insomnia polypharmacy (e.g., co-prescribing with hypnotics, antidepressants, or melatonin agonists)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.